News from the Society for Neuro-Oncology

Haynes JC

European Association of NeuroOncology Magazine 2013; 3 (2)

86
News from the Society for Neuro-Oncology

J Charles Haynes
Society for Neuro-Oncology, Bellaire, TX, USA

The Society for Neuro-Oncology is hard at work organizing the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology which will be held in conjunction with SNO’s 2013 Scientific Meeting and Education Day. The meeting will take place on November 21–24, 2013, in San Francisco, California, at the Marriott Marquis Hotel.

Meeting chairman Dr Mitchel Berger extends a warm welcome to members of all neuro-oncology societies to share in this unique educational event. The meeting is being organized by a committee comprised of representatives of each of the Charter WFNO societies, including Susan Chang and Russell Pieper (SNO), Riccardo Soffietti and Michael Weller (EANO), and Ryo Nishikawa and Koichi Ichimura (ASNO).

The meeting will build on the traditional SNO format of presenting top-scoring abstracts and invited meet-the-expert sessions. The regular deadline for abstract submission is May 22, 2013. New this year, the Society for Neuro-Oncology will allow authors to submit their “Late-Breaking” research for consideration for the 2013 scientific meeting programme. SNO recognizes that some rapidly advancing investigations may include results that will not be available at the time of the abstract submission deadline of May 22, 2013. However, authors should note that this category is not intended to offer a second deadline for regular abstract submissions. Complete details on abstract submission can be found on the SNO website, www.soc-neuro-onc.org.

The meeting will feature an education day entitled “From Drug Discovery to Clinic” which will address the various aspects of clinical development of agents that range from preclinical testing, pharmacokinetic and pharmacodynamic considerations, first-in-man studies, and the challenges of phase-0–III clinical trials. Concurrent sessions will address the specific challenges of clinical design and specific pathways that are being evaluated in the preclinical area.

Running concurrently on education day will be a quality-of-life session with modules focused on palliative care, symptom management, and caregiver challenges.

On Friday evening, a special “Townhall Meeting” is planned that will review the results of the recent international randomized phase-III trials evaluating the use of antiangiogenic strategies for newly diagnosed and recurrent glioblastoma. This special session will provide a forum for open and interactive discussion about how these results may impact clinical care and efforts for further research.

During the meeting, each WFNO Charter Society will present a keynote speaker as follows: Frank McCormick (SNO), Do-Hyun Nam (ASNO), and Stefan Pfister (EANO).

The social highlight of the meeting will be a gala dinner at the magnificent San Francisco City Hall. Please note that registrants who want to attend the gala dinner must buy a separate ticket. Seats are limited, and it is highly recommended to purchase the ticket during on-line registration process as it is likely the gala will be sold out.

A full programme will be posted to the SNO website www.soc-neuro-onc.org in the coming months.

Correspondence to:
J Charles Haynes, JD
Society for Neuro-Oncology
4617 Birch Street, Bellaire, TX 77401-5509, USA
e-mail: chas@soc-neuro-onc.org